Ad5 nCoV, a recombinant adenovirus type 5 vector coronavirus vaccine is being developed by Tianjin CanSino Biotechnology in collaboration with Beijing Institute of Biotechnology for the treatment of COVID-19 infections. CanSinoBIO’s adenovirus-based viral vector vaccine technology platform has been applied to develop the vaccine similar to Ebola virus infection. Clinical development is underway in China.
In May 2020, in continuation with the previous collaboration, The National Research Council (NRC) of Canada and Tianjin CanSino Biotechnology again announced the collaboration to advance bioprocessing and clinical development of Ad5-nCoV, a vaccine against COVID 2019 infections in Canada. According to the collaboration, NRC to advance a scale-up production process for Ad5-nCoV, using its proprietary HEK293 cell line that were designed and developed at the NRC. Both companies will utilize their respective technologies and expertise together to develop the vaccine. As a preparatory step, the Government of Canada had announced $44 million in funding to support upgrades to the NRC's facilities in Montréal to enable compliance with Good Manufacturing Practice (GMP) standards, to ensure readiness for Canadian bioprocessing of potential vaccine candidates as they become available.
Tianjin CanSino Biotechnology is utilising HEK 293 cells and the process developed by National Research Council Canada for the manufacturing of Ad5 adenovirus vector monovalent Ebola virus vaccine.  
Key Development Milestones
In April 2020, CanSino Biologics initiated a phase II trial to evaluate the immunogenicity and safety of Ad5-nCoV in healthy adults aged above 18 years (NCT04341389; JSVCT089). The double blind trial intends to enrol approximately 500 participants in China  .
In March 2020, CanSino Biologics initiated a phase I trial to assess the safety, reactogenicity and immunogenicity of Ad5 nCoV in healthy volunteers (NCT04313127; JSVCT088). The open-label trial will enroll approximately 108 patients in China  .
In March 2020, National medical products administration (NMPA) approved IND (Investigational new drug) application for phase I study of Ad5 nCoV in healthy volunteers in China. The data from preclinical study was used to submit the IND application  .
As of March 2020, Preclinical studies were conducted in animal models by Tianjin CanSino Biotechnology and demonstrated strong immune response with good safety profile  .